PatientsVille.com Logo

Bronchial and Seretide

PatientsVille

Bronchial Symptoms and Causes

When you breathe in, the air travels down through your trachea (windpipe). It then goes through two tubes to your lungs. These tubes are your bronchi. Bronchial disorders can make it hard for you to breathe.

The most common problem with the bronchi is bronchitis, an inflammation of the tubes. It can be acute or chronic. Other problems include

  • Bronchiectasis - a condition in which damage to the airways causes them to widen and become flabby and scarred
  • Exercise-induced bronchospasm - a breathing problem that happens when your airways shrink while you are exercising
  • Bronchiolitis - an inflammation of the small airways that branch off from the bronchi
  • Bronchopulmonary dysplasia - a chronic lung condition in infants, most often premature infants

Check out the latest treatments for bronchial

bronchial treatment research studies

Seretide clinical trials, surveys and public health registries


Find Drug Side Effect reports



Seretide Side Effects

Dyspnoea (295)
Asthma (268)
Death (248)
Cough (140)
Pneumonia (125)
Product Quality Issue (119)
Asthmatic Crisis (85)
Lower Respiratory Tract Infection (72)
Overdose (72)
Respiratory Failure (69)
Fatigue (62)
Chronic Obstructive Pulmonary Disease (61)
Chest Discomfort (61)
Dysphonia (56)
Adrenal Insufficiency (50)
Chest Pain (43)
Tachycardia (40)
Malaise (39)
Dizziness (37)
Headache (36)
Pain (35)
Pyrexia (35)
Condition Aggravated (33)
Cushing's Syndrome (33)
Asthenia (33)
Pruritus (31)
Hypertension (30)
Bronchitis (30)
Tremor (29)
Lung Neoplasm Malignant (29)
Convulsion (28)
Blood Cortisol Decreased (28)
Pulmonary Fibrosis (27)
Wheezing (26)
Myocardial Infarction (26)
Back Pain (26)
Nasopharyngitis (26)
Oedema Peripheral (26)
Pulmonary Embolism (24)
Emphysema (23)
Gait Disturbance (22)
Palpitations (22)
Osteonecrosis (22)
Productive Cough (22)
Bronchospasm (22)
Loss Of Consciousness (21)
Cardiac Failure (21)
Rash (20)
Infarction (20)
Infection (20)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i had suffering asthma since abaut 15 years. but since use seretide inhaler i am feeling more better. but i am affraid seretide inhaler 125 mg for along time. now iam still breast feeding for my third baby. and also iam affraid also increase m

9 yr old son put on Seretide. Psychotic nightmares from day 2. Waking up very distressed. Shakes. fits. Saying 'Help me hlpe me please. I am going to die. Help me please. I am going to kill myself. Oh No. I died. Help me . Help me. There is

After taking Seretide, 9 yr old also complains of stuff stuck in the throat and finding it hard to breath. (As well as pyshcotic nightmares). A disaster of a drug for us. No problems when on flixotide.

After use of Seretide 5 months I get myocardii infarct. I am 63 old man, and I never be ill in past. *DONT_KNOW* *DONT_KNOW*

Been on Seretide for 4 years 125mg 1 puff per day just before bed. For 2.5 years I've been suffering with pain just below my left cage on the side of my torso, panic attacks started 2 years ago only to have been really bad earlier this week. I've jus

Breathing easier but acid indigestion and reflux. Cramp. I stopped taking the seretide evohaler and the terrible acid continued but got easier. The cramp has gone, thank goodness as one muscle would cramp one way and the other would cramp the other,

Developed Asthma after contacting a very bad chest infection. Was hospitalised and prescribed antibiotic and Seride 250 evohaler. Have since developed palpitations and my heart is definitely missing beats particularly when I am in bed. Also have deve

Gain weight

Has anyone noticed any behavioural or mood changes with the use of seretide? My 6 year old son uses it and, following his asthma plan, we increased his dosage from 1 puff morning and night to 2 and he has been very prone to crying, throwing tantrums,

Hi I found seritde powder gave me voice changes,i have now changed to an evo mist inhaler used with a spacer it seems to have cured my problem

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

I am having a horrible experience with this drug (Mucinex DM). Certainly it 'loosens mucous' in my bronchial tubes, but it then seems to pump fluids into my lungs at an alarming rate, and I must force agressive

Bronchial asthma condition ketotifen whether use r not

I am having a horrible experience with this drug (Mucinex DM). Certainly it 'loosens mucous' in my bronchial tubes, but it then seems to pump fluids into my lungs at an alarming rate, and I must force agressive coughing in order to get it o

I had a severe bronchial condition. This med seems to be helping, but a very bad taste in my muth, and stomach gets upset almost to point of vomiting. I wonder if the bad taste is simply the medicine or if it is an opportunistic fungal con

I think I have a build up of bronchial secretions. When I get brochitus -- I do not get a cough. But I feel like just beyone my mouth -- in my wind pipe is a build up of mucus. I do not know to cough it up. Could this be a side effect of arithymyc

Just took the first dose for severe sinus and bronchial infection... so far so good.

Respiratory tract infection (dry cough,fever>38.6) wt is better for fever Aspegic or Voltaren nad why? Is this any relation between the drug used(any of them) and increasing respiratory symptoms? In wt stage of bronchial asthma NSAIDS are contr

Sefretide makes me have bronchial spasms, can't breathe, feel blocked in airways, horseness, numb throat on swallowing, mucus, heavy head...After being very sick for 3 months with cold, bronchitius then pnuemonia. using in halers and very slow on rev

The bad aftertaste is always there! (this is my third time medicating with Biaxin) My colds turn into Bronchial infections, hence, my Doc's use of Biaxin.... This is the FIRST time I've noticed CONFUSION!!!..I am a professional accompanist, and Re

Bronchial Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.
Conditions: House Dust Mite Allergy;   Bronchial Hyperresponsiveness
Intervention: Biological: house dust mite and alternaria allergen Bronchial challenge
Outcome Measures: Safety of Bronchial allergen challenge with house dust mite and alternaria.;   Correlation of predictors like skin prick testing, specific IgE, total IgE, allergen specific dose to PD20 FEV1, nonspecific hyperresponsiveness to methacholine and exhaled NO.;   Development of allergen specific Bronchial hyperreactivity before and after SIT
2 Recruiting Bronchial Hyperreactivity During Histamine Passive Exposure
Conditions: Asthma;   Bronchial Hyperresponsiveness
Intervention: Drug: histamine-benzylic alcohol (magistral preparation)
Outcome Measure: spirometric values in patients exposed passively to histamine during BHR challenge
3 Not yet recruiting Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype
Condition: Asthma
Intervention: Procedure: Bronchial Thermoplasty
Outcome Measures: Asthma Control Test (ACT) score;   Percentage of symptom-free days;   Number of adverse events;   Peak Expiratory Flow (PEF);   Exhaled nitric oxide (NO);   Forced Expiratory Volume in 1 Second (FEV1);   Non-contrast Computed Tomography (CT) scan of the thorax
4 Recruiting Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
Condition: Severe Persistent Asthma
Intervention: Device: catheter ALAIR
Outcome Measures: analysis of the risk and benefit profile with questionnaire ACT and AQLQ;   Analyze the changes in the state of innervation and nerve receptors before and after BT on histological samples of the Bronchial mucosa
5 Recruiting Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests
Condition: Occupational Asthma
Intervention: Other: standardized Bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)
Outcome Measure: Assessment of cellular inflammation in peripheral blood and induced sputum
6 Recruiting Registry of Bronchial Thermoplasty (BT) Procedures EMEA BT Registry.
Condition: Asthma
Intervention: Device: Alair System (Bronchial Thermoplasty)
Outcome Measures: Incidence of severe asthma exacerbations;   Asthma Quality of Life Questionnaire (AQLQ) score;   Emergency department visits for asthma symptoms;   Hospitalizations for asthma symptoms;   Unscheduled office visits including urgent care visits for asthma symptoms.
7 Recruiting Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance
Conditions: Hemoptysis;   Acute Disease
Interventions: Other: Medicals measures;   Other: Bronchial artery embolization
Outcome Measures: Bleeding recurrence rate, after initial therapeutic strategy.;   Evaluation of the rate of serious adverse events
8 Recruiting Adequate Additional Bronchial Cuff Volume to Achieve Blood-tight Seal After Air-tight Seal in Double Lumen Tube
Condition: Preventing Blood Leakage of Bronchial Cuff
Interventions: Procedure: 39 Fr double lumen tube group;   Procedure: 37 Fr double lumen tube group;   Procedure: 35 Fr double lumen tube group
Outcome Measure: leakage of autologus blood through Bronchial cuff
9 Recruiting Study of Physiopathological Mechanisms and Results of Treatment With Bronchial Thermoplasty in Severe Asthma
Condition: Asthma
Intervention: Device: ALAIR Catheter. Radiofrequency system.
Outcome Measures: Bronchial smooth muscle.;   Questionnaire of Quality of life (AQLQ);   Questionnaire of asthma control (ACT);   Number of exacerbations;   Number of hospitalizations;   Respiratory function;   Radiological findings (thorax HRCT scan);   Inflammatory markers
10 Recruiting Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma
Condition: Asthma
Intervention: Device: ALAIR, radiofrequency catheter for Bronchial THERMOPLASTY
Outcome Measures: smooth muscle surface area;   respiratory function
11 Recruiting Study Comparing the Use of Remifentanil Versus Propofol for Performing Bronchial Fibroscopy
Condition: Realisation of Bronchial Fibroscopy
Interventions: Drug: 1: Remifentanil;   Drug: 2: Propofol
Outcome Measures: Duration of patient's caught;   Respiratory frequence and Gaz volume;   Fibroscopist's satisfaction;   Patient's satisfaction;   Pharmacodynamics;   Number of episodes of cough
12 Recruiting A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)
Condition: Asthma
Intervention: Device: Alair system
Outcome Measures: Baseline predictors of response to Bronchial thermoplasty defined by improvement in asthma quality of life, in patients with severe refractory asthma.;   Baseline predictors of severe exacerbations;   Baseline predictors of healthcare utilization;   Baseline predictors of safety of Bronchial thermoplasty;   Predictive models of response to Bronchial thermoplasty
13 Not yet recruiting Efficacy of Bronchial Thermoplasty in Korean
Condition: Asthma
Intervention: Procedure: Bronchial thermoplasty system
Outcome Measures: Quality of Life Questionnaire for Adult Korean Ashtmatics - QLQAKA Questionnaire for Adult Korean Ashtmatics - QLQAKA;   Acute exacerbation
14 Recruiting Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites
Conditions: Bronchial Asthma;   Allergic Rhinitis
Interventions: Drug: sublingual house dust mites allergen extract;   Drug: placebo in sublingual applicator
Outcome Measures: Clinical symptoms of asthma and allergic rhinitis and use of rescue medication;   Change of percent of regulatory lymphocytes in peripheral blood;   assessment of inflammatory markers in exhaled breath condensate and FeNO;   non-specific Bronchial hyperreactivity with methacholine (PC20M), specific conjunctival provocation test
15 Unknown  Treatment of Bronchial Asthma With Borage and Echium Seed Oils
Condition: Bronchial Asthma
Interventions: Dietary Supplement: Borage Seed Oil and Echium Seed Oil;   Dietary Supplement: Corn Oil
Outcome Measures: FEV1;   Peak flows;   Symptoms of Bronchial asthma;   Frequency of rescue use of short acting beta-2 agonists;   Ex vivo leukotriene generation;   Plasma fatty acid content
16 Recruiting Different End Points for Bronchial Hyperactivity (BHR) Tests.
Condition: Bronchial Hyperreactivity
Intervention:
Outcome Measures: Which of the outcome ends points measures comes first in the diagnosis of BHR.;   Age influence on which comes first outcomes.
17 Unknown  Omalizumab in Non-atopic Asthma
Condition: Bronchial Asthma
Interventions: Drug: Omalizumab;   Drug: Placebo
Outcome Measures: Pre-bronchodilator FEV1;   Disease exacerbation;   Day and night time symptom scores;   Morning and evening peakflows;   Exhaled nitric oxide;   Total dosage of rescue beta-2-agonists;   Total symptom free days;   Quality of life scores;   Markers of airway remodelling and inflammation;   Local IgE synthesis in the Bronchial mucosa and its expression
18 Recruiting Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069
Condition: Asthma
Intervention: Drug: AZD5069
Outcome Measures: Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of Neutrophil cell counts, in Bronchial mucosal tissue and Induced sputum;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of neutrophil cell counts - Blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of GRO-α, MMP-9 and IL8 - Bronchial mucosal tissue samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of GRO-α, MMP and IL-8 - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of GRO-α, MMP and IL-8 in blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of eosinophil%, lymphocytes %, basophils % and monocytes/macrophages % change cell counts - Bronchial mucosal tissue;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of eosinophil % change cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of lymphocytes % change cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of basophils % change cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms monocytes/macrophages % change cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms eosinophil total cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms lymphocytes total cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of basophils total cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms monocytes/macrophages total cell counts - blood;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of eosinophil % change cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of basophils % change cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of monocytes/macrophages % change cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of eosinophil total cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of lymphocytes total cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of basophils total cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of monocytes/macrophages total cell counts - induced sputum samples;   Description of pharmacodynamic effect of AZD 5069 as a change from baseline in terms of FEV1 and FVC before the morning dose compared to baseline;   Description of pharmacokinetics of AZD 5069 in terms of Cmin The lowest through plasma concentration before drug administration;   Description of pharmacokinetics in terms of Cmax The highest plasma concentration at visit 7;   Description of pharmacokinetics in terms of AUC0-4hrs Area under the plasma concentration curve at visit 7;   Description of pharmacokinetics in terms of tmax Time to reach Cmax at visit 7;   Description of the safety profile in terms of Adverse events, Vital signs, ECG and safety laboratory
19 Unknown  Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording
Condition: Asthma, Bronchial
Intervention: Device: PulmoTrack® 2010 with WIM-PC™ Technologies
Outcome Measures: Study success will be declared if one of the following is met: A correlation of at least 0.25 (R2=0.25) will be found between WR and FEV1 measurements; A correlation of at least 0.7 will be found between clinical parameter and WZ measurements.;   Evaluation of the safety of using the PulmoTrack® 2010 with WIM-PC™ Technologies for wheeze detection. Safety will be established by lack of adverse events. Since this is a Non Significant Risk (NSR) device serious adverse events are not expected
20 Recruiting Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI
Condition: Asthma
Interventions: Drug: HXe MRI guided treatment sequence for BT;   Other: Standard treatment sequence for BT (control)
Outcome Measures: Change in Asthma Quality of Life Questionnaire (AQLQ) from baseline;   Assessment of HXe MRI as an imaging biomarker for asthma disease severity